Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of neoGAA in Pompe disease
NL-OMON55395Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Sep 2014
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of avalglucosidase alfa in Pompe disease (3 arms), sponsored by Sanofi. Primary endpoint: Long-term safety of neoGAA. Started Sep 2014; status: active, not recruiting.
02
Drugs
avalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NL-OMON55395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55395.